Emerson 4000 THRESHOLD LIMIT VALUE, EFFECTS OF OVER EXPOSURE, EXPOSURE TO USED CERAMIC FIBER PRODUCT, SPECIAL TOXIC EFFECTS, SECTION V. HEALTH HAZARD DATA, EYE, SKIN

Oxymitter 4000

Instruction Manual

IB-106-340 Rev. 3.0 December 2003

SECTION V. HEALTH HAZARD DATA

THRESHOLD LIMIT VALUE

(See Section III)

EFFECTS OF OVER EXPOSURE

EYE

Avoid contact with eyes. Slightly to moderately irritating. Abrasive action may cause damage to outer surface of eye.

INHALATION

May cause respiratory tract irritation. Repeated or prolonged breathing of particles of respirable size may cause inflammation of the lung leading to chest pain, difficult breathing, coughing and possible fibrotic change in the lung (Pneumo- coniosis). Pre-existing medical conditions may be aggravated by exposure: specifically, bronchial hyper-reactivity and chronic bronchial or lung disease.

INGESTION

May cause gastrointestinal disturbances. Symptoms may include irritation and nausea, vomiting and diarrhea.

SKIN

Slightly to moderate irritating. May cause irritation and inflammation due to mechanical reaction to sharp, broken ends of fibers.

EXPOSURE TO USED CERAMIC FIBER PRODUCT

Product which has been in service at elevated temperatures (greater than 1800ºF/982ºC) may undergo partial conversion to cristobalite, a form of crystalline silica which can cause severe respiratory disease (Pneumoconiosis). The amount of cristobalite present will depend on the temperature and length of time in service. (See Section IX for permissible exposure levels).

SPECIAL TOXIC EFFECTS

The existing toxicology and epidemiology data bases for RCF’s are still preliminary. Information will be updated as studies are completed and reviewed. The following is a review of the results to date:

EPIDEMIOLOGY

At this time there are no known published reports demonstrating negative health outcomes of workers exposed to refractory ceramic fiber (RCF). Epidemiologic investigations of RCF production workers are ongoing.

1)There is no evidence of any fibrotic lung disease (interstitial fibrosis) whatsoever on x-ray.

2)There is no evidence of any lung disease among those employees exposed to RCF that had never smoked.

3)A statistical “trend” was observed in the exposed population between the duration of exposure to RCF and a de- crease in some measures of pulmonary function. These observations are clinically insignificant. In other words, if these observations were made on an individual employee, the results would be interpreted as being within the nor- mal range.

Rosemount Analytical Inc. A Division of Emerson Process Management P-17